Next Article in Journal
Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
Previous Article in Journal
The Role of Radiation Induced Injury on Lung Cancer
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
Cancers 2017, 9(7), 90; doi:10.3390/cancers9070090

SIRT3: Oncogene and Tumor Suppressor in Cancer

1
Grupo Multidisciplinar de Oncología Traslacional, Institut Universitari d´Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Balears. Cra de Valldemossa, km 7.5, 07122 Palma, Illes Balears 07122, Spain
2
Ciber Fisiopatología Obesidad y Nutrición (CB06/03) Instituto Salud Carlos III, Madrid 28029, Spain
3
Instituto de Investigación Sanitaria de Baleares (IdISBa), Hospital Universitario, Son Espases, edificio S. E-07120 Palma, Palma de Mallorca, Illes Balears 07120, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Samuel C. Mok
Received: 4 May 2017 / Revised: 2 July 2017 / Accepted: 7 July 2017 / Published: 12 July 2017
View Full-Text   |   Download PDF [885 KB, uploaded 12 July 2017]   |  

Abstract

Sirtuin 3 (SIRT3), the major deacetylase in mitochondria, plays a crucial role in modulating oxygen reactive species (ROS) and limiting the oxidative damage in cellular components. SIRT3 targets different enzymes which regulate mitochondrial metabolism and participate in ROS detoxification, such as the complexes of the respiratory chain, the isocitrate dehydrogenase, or the manganese superoxide dismutase. Thus, SIRT3 activity is essential in maintaining mitochondria homeostasis and has recently received great attention, as it is considered a fidelity protein for mitochondrial function. In some types of cancer, SIRT3 functions as a tumoral promoter, since it keeps ROS levels under a certain threshold compatible with cell viability and proliferation. On the contrary, other studies describe SIRT3 as a tumoral suppressor, as SIRT3 could trigger cell death under stress conditions. Thus, SIRT3 could have a dual role in cancer. In this regard, modulation of SIRT3 activity could be a new target to develop more personalized therapies against cancer. View Full-Text
Keywords: SIRT3; cancer; ROS; antioxidant enzymes; mitochondria SIRT3; cancer; ROS; antioxidant enzymes; mitochondria
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Torrens-Mas, M.; Oliver, J.; Roca, P.; Sastre-Serra, J. SIRT3: Oncogene and Tumor Suppressor in Cancer. Cancers 2017, 9, 90.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top